3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Myeloproliferative Disorders
1
Blast Crisis
1
Interventions
Specimen Handling
415
Magnetic Resonance Spectroscopy
332
pembrolizumab
261
Biopsy
227
Carboplatin
216
Cisplatin
179
Cyclophosphamide
174
Paclitaxel
148
Nivolumab
135
Gemcitabine
130
Radiotherapy
120
Dexamethasone
105
Bevacizumab
101
fludarabine
95
Radiation
94
Fluorouracil
93
Pemetrexed
88
Doxorubicin
88
Docetaxel
83
Rituximab
82
venetoclax
81
durvalumab
81
Oxaliplatin
81
Leucovorin
76
atezolizumab
68
Lenalidomide
66
Capecitabine
66
Prednisone
65
Etoposide
64
Vincristine
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
bosutinib
×
30 days
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled
NCT04626024
2026-05-04
TOKIN
Baylor College of Medicine
Phase 2
Active not recruiting
17 enrolled